In the latest legal update, we direct your attention towards the recent Federal Court cases of September 2023. An appeal that stands out among these is “Baxalta Inc. v. Genentech, Inc.”, referenced as Appeal No. 22-1461. The case unfolded on September 20th, 2023. The primary point of interest revolves around the ‘enablement’ requirement, marking its significance in patent law.
For a quick recall, ‘enablement’ made quite a stir earlier this year in “Amgen Inc. v. Sanofi”, 598 U.S. 495, under the Supreme Court’s judgement(JD Supra). This case serves as the first instance where the matter of ‘enablement’ has come forth for discussion following the Supreme Court’s resolution on the topic.
Tracing the judgment on Baxalta Inc. v. Genentech, Inc., the panel of the Circuit agreed unanimously that the broader claims encompassing an entire class of antibodies weren’t completely ‘enabled’ by the patent specification. The verdict puts forth the significance of introducing a patent that encapsulates specific claims about a class of antibodies, rather than opting for a broad, non-specific approach.
The dichotomy between a specific patent claim versus a broad approach is yet another emphasis in continuation from the Amgen Inc. v. Sanofi judgement. The debate continues, casting a distinct shadow on the way forward for patent law practitioners and professionals.